Share on StockTwits

Analysts at Canaccord Genuity increased their price objective on shares of Vernalis plc (LON:VER) from GBX 52 ($0.87) to GBX 54 ($0.91) in a research report issued to clients and investors on Thursday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target points to a potential upside of 43.05% from the company’s current price.

A number of other analysts have also recently weighed in on VER. Analysts at N+1 Singer reiterated a “buy” rating on shares of Vernalis plc in a research note on Tuesday, August 5th. They now have a GBX 42 ($0.70) price target on the stock. Separately, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Vernalis plc in a research note on Monday, August 4th. They now have a GBX 60 ($1.01) price target on the stock. Finally, analysts at Oriel Securities Ltd reiterated a “buy” rating on shares of Vernalis plc in a research note on Tuesday, July 22nd. They now have a GBX 60 ($1.01) price target on the stock. Six research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of GBX 49.50 ($0.83).

Vernalis plc (LON:VER) opened at 38.00 on Thursday. Vernalis plc has a 52 week low of GBX 24.25 and a 52 week high of GBX 38.75. The stock has a 50-day moving average of GBX 32.48 and a 200-day moving average of GBX 33.75.

Vernalis plc is a research and development-stage pharmaceutical company. Vernalis has one marketed product and a portfolio of development and drug discovery programmes.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.